UB-221

• Description :

  UB-221 is a humanized IgG1 monoclonal antibody inhibitor targeting IgE. UB-221 significantly decreases IgE synthesis by stabilization of membrane-bound CD23 on B lymphocytes and inhibits FcԑRI-mediated basophil activation and degranulation. UB-221 reduces IgE level in cynomolgus macaques and human IgE (ε, κ) -transgenic (hIGHE-knockin) mice. UB-221 can be used for asthma and chronic spontaneous urticaria (CSU) research[1].

• CAS Number :

  [2755114-30-6]

• UNSPSC :

  12352203

• Target :

  Others

• Related Pathways :

  Others

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• References & Citations :

  [1]Kuo BS, et al. IgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE downregulation and relieves urticaria symptoms. J Clin Invest. 2022 Aug 1;132 (15) :e157765. |[2]Casale TB. Novel biologics for treatment of chronic spontaneous urticaria. J Allergy Clin Immunol. 2022 Dec;150 (6) :1256-1259.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Inhibitory Antibodies

• Clinical Information :

  No Development Reported